Proteostasis Therapeutics (NASDAQ:PTI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage currently has a $8.25 price target on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 50.82% from the company’s current price.

According to Zacks, “Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. “

How to Become a New Pot Stock Millionaire

PTI has been the topic of a number of other reports. ValuEngine cut shares of Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Robert W. Baird upped their price target on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Leerink Swann upped their price target on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a report on Tuesday, December 12th. Royal Bank of Canada began coverage on shares of Proteostasis Therapeutics in a report on Friday, March 9th. They issued an “outperform” rating and a $11.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $13.45.

Proteostasis Therapeutics (NASDAQ PTI) opened at $5.47 on Tuesday. The company has a market cap of $241.03, a PE ratio of -2.33 and a beta of 6.66. Proteostasis Therapeutics has a 1-year low of $1.41 and a 1-year high of $13.16.

Institutional investors have recently modified their holdings of the business. Jefferies Group LLC bought a new position in Proteostasis Therapeutics during the 4th quarter worth about $175,000. Jane Street Group LLC bought a new position in Proteostasis Therapeutics during the 4th quarter worth about $203,000. Goldman Sachs Group Inc. bought a new position in Proteostasis Therapeutics during the 4th quarter worth about $354,000. Dimensional Fund Advisors LP bought a new position in Proteostasis Therapeutics during the 2nd quarter worth about $296,000. Finally, Sectoral Asset Management Inc bought a new position in Proteostasis Therapeutics during the 4th quarter worth about $1,749,000. Institutional investors own 70.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/zacks-investment-research-upgrades-proteostasis-therapeutics-pti-to-buy/1955403.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.